Ken Griffin Dyne Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 943,874 shares of DYN stock, worth $11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
943,874
Previous 33,400
2725.97%
Holding current value
$11 Million
Previous $349,000
2474.5%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding DYN
# of Institutions
210Shares Held
122MCall Options Held
36.5KPut Options Held
74.3K-
Ra Capital Management, L.P. Boston, MA9.71MShares$113 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$110 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$106 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$88.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$85.8 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $602M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...